The IPO, which consists of a fresh issue of Rs 95 crore and an offer for sale of up to 1.35 crore shares, will remain open till November 25. At the higher end of the price range, the issue size totals Rs 895 crore. The gray market premium (GMP) is currently around 20%, indicating moderate listing expectations.
Business snapshot
Sudeep Pharma is a technology-led manufacturer of excipients and specialty ingredients used in pharmaceuticals, foods and nutrition. The company produces more than 100 products and has built capabilities in encapsulation, spray drying, granulation, trituration, liposomal processes and blending. It is also one of the world’s largest producers of food-grade iron phosphate used in infant and clinical nutrition.
The company has an annual production capacity of 72,246 tonnes and has regulatory approvals, including a USFDA approved facility for mineral-based ingredients, a significant advantage for global supply. The company exports to the US, South America, Europe, the Middle East, Africa and Asia Pacific.
The financial performance is stable. Revenue grew from Rs 428.7 crore in FY23 to Rs 502 crore in FY25, while net profit rose from Rs 60.4 crore to Rs 137 crore in the same period. In the first quarter of FY26, the company reported a revenue of Rs 124.9 crore and a profit of Rs 28.4 crore.
Sector context
The Indian food and nutritional ingredients market is growing rapidly, supported by rising health consciousness and growing disposable income. The total food ingredients market, estimated at USD 22 billion in 2024, is expected to reach USD 32 billion by 2029, at a CAGR of 8.1%. The vitamin and mineral segment alone will represent a $2.1 billion market in 2024 and is expected to grow to $3 billion by 2029.The domestic pharmaceutical sector is also expected to reach $130 billion by 2030 and possibly $450 billion by 2047. With the growing demand for specialty ingredients in drug and nutritional formulations, Sudeep Pharma finds itself at the heart of multiple long-term growth trends.
Broker’s vision: think about the long term
Master Capital Services has given a positive assessment of the IPO, citing the company’s positioning in a fast-growing market and the advantage of its technology-driven production capabilities.
The brokerage notes that the rapid expansion of the Indian pharmaceutical, food and nutrition markets creates a favorable backdrop for Sudeep Pharma’s product portfolio. With strong in-house process technologies, a diverse product offering and an established export presence, the company is “strategically positioned to capture future growth opportunities.”
Master Capital recommends that investors view the issue as a potential long-term investment given the structural tailwinds in the ingredients and specialty chemicals ecosystem.
IPO structure
Approximately 50% of the offering is reserved for qualified institutional buyers, up to 15% for high net worth investors and 35% for retail investors. Investors can bid for a minimum of 25 shares and in multiples thereafter. ICICI Securities and IIFL Capital Services are the lead managers and MUFG Intime India is the registrar.
What to watch
The next trigger will be subscription trends within QIBs and retail categories, especially given the strong anchor participation. With a GMP of 20% and constructive commentary from brokers, sentiment heading into Day 1 remains positive, although actual demand will determine how comfortably the IPO crosses the finish line.
The application window closes on November 25th and allocations are due on November 26th. The stock is likely to list on November 28, where the real test of investor appetite will take place.
(Disclaimer: Recommendations, suggestions, views and opinions expressed by the experts are their own. These do not represent the views of the Economic Times)
#Mukul #Agrawalbacked #Sudeep #Pharma #IPO #kicks #today #strong #GMP #bid